Isto Biologics

Isto produces allograft bone void fillers, cellular bone matrices, and autologous cell-processing systems. Its products serve orthopedic surgeons working in spine, trauma, sports medicine, and foot-and-ankle reconstruction. The portfolio includes the Influx family of bone-graft substitutes and the Invia cellular matrix.

Isto operates a vertically integrated model in St. Louis that houses donor-tissue recovery coordination, processing suites, cell-culture labs, and finished-product sterilization under one roof. This single-campus configuration means the firm manages quality from donor-screening through surgical distribution rather than contracting out critical steps.

Isto distributes through a hybrid model combining direct sales to hospital networks with independent distributor relationships. The company holds supply agreements with integrated delivery networks including Mercy Health and the U.S. Department of Defense for military treatment facilities.

Isto operates under FDA regulations for human cells, tissues, and cellular and tissue-based products (HCT/Ps). Its St. Louis facility holds accreditation from the American Association of Tissue Banks, most recently recertified in August 2023, confirming compliance with current Good Tissue Practice standards.

The orthobiologics space includes publicly traded companies such as Medtronic (through its Infuse bone graft and spinal biologics division) and RTI Surgical, alongside private firms like AlloSource in Colorado. Isto competes primarily in the allograft and cellular bone-matrix segments rather than the recombinant-protein segment dominated by Medtronic.